Purpose: To evaluate the influence of ibuprofen treatment on urinary PGE2 excretion. Methods: Forty premature infants with gestational age (GA <33 weeks) were studied prospectively. Case group: 20 infants (GA, 28.6 ± 2.3 weeks; birth weight, 1,142 ± 356 g) with a significant PDA at 48-72 h of age, treated with ibuprofen. Control group: 20 infants (GA, 30.4 ± 1.5 weeks; birth weight, 1,469 ± 510 g) without PDA. 2 serial urine samples were noninvasively collected T0, pre-treatment, T1, post-treatment, respectively. Urinary PGE2 concentrations were measured by enzyme immunoassay. Results: Urinary PGE2 concentration significantly decreased with time in both cases (from 67 ± 16.8 to 27.2 ± 17.9 pg/ml, p < 0.001) and controls (from 71.7 ± 16.2 to 53.2 ± 18.4 pg/ml, p < 0.001), but it was significantly lower in ibuprofen-treated group at T1 (p < 0.001). There were no significant differences between cases and controls in the rate of mortality and renal, intestinal and cerebral morbidities. Acute renal failure (n = 3), necrotizing enterocolitis (n = 2), and intraventricular hemorrhage (n = 1) occurred in 4 ibuprofen-treated infants who had a marked (>70%) reduction in urinary PGE2 with respect to baseline. Conclusion: Urinary PGE2 physiologically decreases in preterm infants during the first week of life, but ibuprofen treatment significantly enhances this decrease. Ibuprofen-induced morbidities seem to be associated with a dramatic reduction in urinary PGE2.

Urinary PGE2 changes after ibuprofen treatment in preterm infants with patent ductus arteriosus / Antonucci, Roberto; Cuzzolin, L; Arceri, A; Cataldi, L; Fanos, V.. - In: BIOLOGY OF THE NEONATE. - ISSN 0006-3126. - 90:(2006), p. 278.

Urinary PGE2 changes after ibuprofen treatment in preterm infants with patent ductus arteriosus

ANTONUCCI, Roberto;
2006-01-01

Abstract

Purpose: To evaluate the influence of ibuprofen treatment on urinary PGE2 excretion. Methods: Forty premature infants with gestational age (GA <33 weeks) were studied prospectively. Case group: 20 infants (GA, 28.6 ± 2.3 weeks; birth weight, 1,142 ± 356 g) with a significant PDA at 48-72 h of age, treated with ibuprofen. Control group: 20 infants (GA, 30.4 ± 1.5 weeks; birth weight, 1,469 ± 510 g) without PDA. 2 serial urine samples were noninvasively collected T0, pre-treatment, T1, post-treatment, respectively. Urinary PGE2 concentrations were measured by enzyme immunoassay. Results: Urinary PGE2 concentration significantly decreased with time in both cases (from 67 ± 16.8 to 27.2 ± 17.9 pg/ml, p < 0.001) and controls (from 71.7 ± 16.2 to 53.2 ± 18.4 pg/ml, p < 0.001), but it was significantly lower in ibuprofen-treated group at T1 (p < 0.001). There were no significant differences between cases and controls in the rate of mortality and renal, intestinal and cerebral morbidities. Acute renal failure (n = 3), necrotizing enterocolitis (n = 2), and intraventricular hemorrhage (n = 1) occurred in 4 ibuprofen-treated infants who had a marked (>70%) reduction in urinary PGE2 with respect to baseline. Conclusion: Urinary PGE2 physiologically decreases in preterm infants during the first week of life, but ibuprofen treatment significantly enhances this decrease. Ibuprofen-induced morbidities seem to be associated with a dramatic reduction in urinary PGE2.
Urinary PGE2 changes after ibuprofen treatment in preterm infants with patent ductus arteriosus / Antonucci, Roberto; Cuzzolin, L; Arceri, A; Cataldi, L; Fanos, V.. - In: BIOLOGY OF THE NEONATE. - ISSN 0006-3126. - 90:(2006), p. 278.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/66612
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact